Monopar Therapeutics Inc. (MNPR) Misses Q3 EPS by 27c

Monopar Therapeutics Inc. (NASDAQ: MNPR) reported Q3 EPS of ($0.37), $0.27 worse than the analyst estimate of ($0.10).

For earnings history and earnings-related data on Monopar Therapeutics Inc. (MNPR) click here.

You May Also Be Interested In

• Oracle (ORCL) PT Lowered to $290 at Jefferies
• Morgan Stanley Starts Amplifon SpA (AMP:IM) (AMFPF) at Overweight
• Dell Technologies (DELL) Tops Q2 EPS by $2.17, Offers Guidance